← All trials
NCT04488016
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2020
- Primary completion
- Dec 22, 2020
- Completion date
- Dec 22, 2020
- First posted
- Jul 27, 2020
- Last posted
- Nov 9, 2020
- Enrollment
- 42
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- ParexelOverall official - principal investigator
- Acerta PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.